The combined use of a Tim-3 inhibitor and MT110 (anti-CD3× anti-EpCAM) could enhance the anti-tumor effect of the adoptively transfused γδ T cells, which have clinical implications for the design of new anti-tumor regimens (81). The gene discussed is HAVCR2; the disease is neoplasm.